Toggle navigation
Menu
About Us
Investment Strategy
Team
Portfolio
News
Contact Us
Limited Partners
Portfolio
Molecular Partners
Develops a proprietary new class of drugs called DARPins - "Antibody v. 2.0"
Transaction Summary
Completed a $100M IPO in 2014
Lead product, abicipar, started pivotal Phase III clinical trials for AMD - leading cause of blindness
Zurich-Schlieren, Switzerland
SIX: MOLN
Contact:
Petri Vainio
www.molecularpartners.com
IPO
Related News
Molecular Partners Wins European Biotechnica Award 2015
Bill Burns Nominated for Election to Molecular Partners’ Board of Directors
Allergan Strengthens DARPin Development and Discovery Alliance with Molecular Partners
Molecular Partners’ Partner Allergan Exercises Options for Two DARPin Product Candidates